$CORT News

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

What Corcept Therapeutics Stock Positive Trial Results Mean For Shareholders

Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Announces Results From Part A Of Its Phase 2 BELLA Trial Of Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab In Patients With Ovarian Cancer; Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab Demonstrated Clinically Meaningful Progression-Free Survival, Objective Response Rate And Overall Survival

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

Corcept Therapeutics (CORT) Stock Looks Fully Priced For Its Sales Story

Corcept Therapeutics (CORT) Draws Options Attention, Is It Still 18% Below Fair Value?

Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock?

Corcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings Growth

3 Reasons to Sell CORT and 1 Stock to Buy Instead

Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)

Corcept Announces Planned Leadership Transition

Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $165 Price Target

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years

Corcept Therapeutics (NASDAQ:CORT) Combines Strong Growth With a Constructive Technical Setup